We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Growth hormone retesting during puberty: a cohort study.
- Authors
Cavarzere, Paolo; Gaudino, Rossella; Sandri, Marco; Ramaroli, Diego Alberto; Pietrobelli, Angelo; Zaffanello, Marco; Guzzo, Alessandra; Salvagno, Gian Luca; Piacentini, Giorgio; Antoniazzi, Franco
- Abstract
Objectives: To report the frequency and characteristics of growth hormone (GH) deficiency (GHD) in adolescents who had normalized GH secretion at mid-puberty and to identify poss ible factors predictive for GH sufficiency at puberty. Design: Clinical analysis of children affected by GHD at five time point s: diagnosis; first year of therapy; intermediate stage of puberty; retesting and end of growth phase. Methods: The study population was 80 children with idiopathic GHD and t reated with GH for at least 2 years. Treatment was discontinued at the intermediate stage of puberty. Retestin g with an arginine test was performed 12 weeks later. If GH peak at retesting was =8 µg/L, the therapy was definitively discontinued, otherwise it was restarted and continued until achievement of near-final height. Results: GH therapy was discontinued in 44 children (55%), and restarte d in 36 (45%). No evidence of differences in definitive height and in the delta height between the genetic ta rget and the definitive height was found between the two groups. The only predictive factor for GHD at mid-puberty w as the insulin growth factor-1 (IGF-1) level at 1 year of GH treatment. Conclusions: GH secretion should be retested at mid-puberty. Retesting at p uberty may reduce potential side effects and minimize costs, without impairing growth potential and final height.
- Subjects
SOMATOTROPIN; PITUITARY dwarfism; PUBERTY; COHORT analysis; DRUG side effects; INSULIN
- Publication
European Journal of Endocrinology, 2020, Vol 182, Issue 6, p559
- ISSN
0804-4643
- Publication type
Article
- DOI
10.1530/EJE-19-0646